These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30677005)

  • 21. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 22. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
    Küronya Z; Bíró K; Gyergyay F; Géczi L
    Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progress of the treatment for CRPC].
    Ozono S; Furuse H
    Nihon Rinsho; 2016 May; 74 Suppl 3():615-8. PubMed ID: 27344804
    [No Abstract]   [Full Text] [Related]  

  • 24. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 25. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing advanced prostate cancer: the rapidly changing treatment landscape.
    Dreicer R
    Am J Manag Care; 2014 Dec; 20(12 Suppl):S282-9. PubMed ID: 25734964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
    Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
    Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
    [No Abstract]   [Full Text] [Related]  

  • 28. Many FDA-approved cancer drugs might lack clinical benefit.
    Das M
    Lancet Oncol; 2018 Feb; 19(2):e82. PubMed ID: 29276024
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate cancer: Validating early PSA response to enable improved treatment decisions.
    Thoma C
    Nat Rev Urol; 2016 May; 13(5):239. PubMed ID: 27001015
    [No Abstract]   [Full Text] [Related]  

  • 30. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
    Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G
    Anticancer Drugs; 2015 Sep; 26(8):910-1. PubMed ID: 26207428
    [No Abstract]   [Full Text] [Related]  

  • 31. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 32. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
    Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
    Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
    [No Abstract]   [Full Text] [Related]  

  • 33. [Docetaxel and prostate cancer: Early but not too early].
    Penel N; Ryckewaert T; Amela EY
    Bull Cancer; 2015 Sep; 102(9):710-2. PubMed ID: 26235414
    [No Abstract]   [Full Text] [Related]  

  • 34. Emerging drugs for prostate cancer.
    Chung PH; Gayed BA; Thoreson GR; Raj GV
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):533-50. PubMed ID: 24274615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drugs in the treatment of elderly patients with metastatic castration-resistance prostate cancer.
    Genestreti G; Di Battista M; Cavallo G; Brandes AA
    Tumori; 2016 Aug; 102(4):361-6. PubMed ID: 27151879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
    Pinto A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer drugs remain FDA approved despite lack of benefit, study finds.
    McCarthy M
    BMJ; 2016 Dec; 355():i6568. PubMed ID: 27923801
    [No Abstract]   [Full Text] [Related]  

  • 38. Updates on radium-223 for castration-resistant prostate cancer presented at the Genitourinary Cancers Symposium, January 7-9, 2016, San Francisco, California.
    Barkin J
    Can J Urol; 2016 Jun; 23(3):8306-7. PubMed ID: 27347626
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy Update for Metastatic Castration-Resistant Prostate Cancer.
    Dinh JA; Baker D; Chahal M
    Consult Pharm; 2016; 31(10):581-592. PubMed ID: 27725068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
    Dorff TB; Wilkins C; Hepgur M; Quinn DI
    Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.